Recent reports suggest that U. S. Food and Drug Administration has approved a new treatment for bronchospasm (narrowing of the airways in the lung). Tudorza Pressair (aclidinium bromide), is a Dry powder inhaler (DPI). It is a device that delivers medication to the lungs in the form of a dry powder.

This condition is linked with chronic obstructive pulmonary disease (COPD). A person suffering from COPD is hit by either chronic bronchitis or emphysema, a pair of commonly co-existing diseases of the lungs in which the airways become narrowed. This leads to a limitation of the flow of air to and from the lungs, causing shortness of breath.

It has been stated that the inhaler is a long-acting antimuscarinic agent removes the blockage from the airways, thus relaxing the airways and also improving the flow of air.

National Heart, Lung, and Blood Institute has suggested that the problem of COPD majorly arises due to smoking cigarette. Nevertheless, COPD has been considered as the fourth largest condition, due to which many people die in United States.

Curtis Rosebraugh from FDA’s Center for Drug Evaluation and Research, said “The availability of long-term maintenance drugs for COPD provides additional treatment options for the millions of people who suffer with this debilitating disease”.